Navegando por Autor "Rezende, Adriana Augusto"
Agora exibindo 1 - 6 de 6
- Resultados por página
- Opções de Ordenação
Artigo Association between kidney function and Framingham risk score in an admixed population of Brazil(Brazilian Journal of Pharmaceutical Sciences, 2018-02) Evangelista, Karine Cavalcanti Maurício de Sena; Costa, Brunna Soares Rodrigues; Freitas, Erika Paula Silva; Cruz, Marina Sampaio; Duarte, Victor Hugo Rezende; Silva, Ananília Medeiros Gomes da; Santos, Isabelle Cristina Clemente dos; Santos, Jéssica Cavalcante dos; Rezende, Adriana Augusto; Silbiger, Vivian NogueiraChronic kidney disease (CKD) increases cardiovascular disease (CVD) risk development. However, the mechanisms of reduced kidney function with CVD risk are unclear. This study aimed to investigate the association between kidney function and Framingham risk score (FRS) in participants with traditional cardiovascular risk factors and normal estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m² in an admixed population of Brazil. The participants were divided into three groups according to FRS: low risk group with 0% to <10%, moderate risk group with ≥10% to 20% and high risk group with >20%. The eGFR was calculated using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI). Data from participants were collected by questionnaire, and blood and urine samples were collected to analyze biochemical markers. A total of 214 subjects aged 53±10 years old was collected. There were 77 individuals in low risk group, 59 in moderate risk group and 78 in high-risk group. Mean eGFRCKD-EPI was 89.39±15.05 mL/min/1.73 m² and 90.74±16.17 mL/min/1.73 m2 when race adjustment. The results indicated that there is an increasing the cardiovascular risk with a decreased of eGFR, conforming to a significant inverse correlation observed between eGFR and FRS with Spearman correlation (R²=-0.256, p<0.001; R²=-0.224, p=0.001, when adjusted for race). There was a statistically significant difference in eGFRCKD-EPI (p<0.001) and eGFRCKD-EPI with race adjustment (p=0.002) among risk groups. The data suggests that the reduction eGFR is associated with elevated FRS among Brazilian adults without CKD. Furthermore, the results suggest that race adjustment it’s not necessary in Brazilian populationArtigo Association of serum alpha-tocopherol and retinol with the extent of coronary lesions in coronary artery disease(Journal of Nutrition and Metabolism, 2018-12-11) Ribeiro, Karla Danielly da Silva; Miranda, Carolinne Thaísa de Oliveira Fernandes; Duarte, Victor Hugo Rezende; Cruz, Marina Sampaio de Menezes; Duarte, Mychelle Kytchia Rodrigues Nunes; Araújo, Jéssica Nayara Góes de; Santos, Ayda Maria Quirino Silva dos; Oliveira, Juliana Marinho de; Paiva, Maria Sanali Moura Oliveira; Rezende, Adriana Augusto; Hirata, Mario Hiroyuki; Hirata, Rosario Dominguez Crespo; Luchessi, André Ducati; Silbiger, Vivian Nogueira; https://orcid.org/0000-0001-7708-4271; https://orcid.org/0000-0003-3073-5967; https://orcid.org/0000-0002-9252-0278; https://orcid.org/0000-0002-2251-5967; https://orcid.org/0000-0002-3122-9073; https://orcid.org/0000-0002-2276-690X; https://orcid.org/0000-0003-2452-4047; https://orcid.org/0000-0002-9521-7979; https://orcid.org/0000-0002-2758-8102Background and aims: Fat-soluble vitamins play an important role in the pathogenesis of cardiovascular disease and progression ofatherosclerosis. +is study aimed at investigating the relationship of the serum levels of alpha-tocopherol and retinol with theextent of coronary lesions in patients with coronary artery disease. Methods. Patients with coronary artery disease (n = 177) aged 30 – 74 years, who underwent their first coronary angiography, were enrolled. The extent of coronary lesions was assessed using th eFriesinger index (FI). Accordingly, patients were grouped as follows: FI = 0–4 (n = 90), FI = 5–9 (n = 50), and FI = 10–15 (n = 37).Serum levels of vitamins were determined via high-performance liquid chromatography and serum biochemical analysis. Results.Assessment of FI-based groups revealed that 50.8% patients had a coronary artery lesion to a low extent (FI 0–4). Individuals inthis group were younger and had lower glucose and serum alpha-tocopherol levels than the other groups (p < 0.05). Low levels of alpha-tocopherol were more frequent in the FI 0–4 group than that in the other groups (p = 0.03). No difference was observedbetween the mean serum retinol levels among the FI-based groups (n = 0.492), and the low frequency of retinol was consistentamong the FI groups (n = 0.348). Conclusions. The low level of alpha-tocopherol together with the presence of dyslipidemia isprobably associated with the initial events in atherosclerosis. Increased alpha-tocopherol levels in patients with more extensivecoronary artery lesions may have resulted from altered vitamin E metabolism with increased oxidative stress.TCC Criação de um guia para acompanhamento farmacêutico de pacientes com síndrome metabólica(Universidade Federal do Rio Grande do Norte, 2022-06-29) Costa, Ana Carina Farias da; Rezende, Adriana Augusto; Araújo, Ivonete Batista de; Souza, Karla Simone CostaINTRODUÇÃO: A Síndrome metabólica, (SM), transtorno complexo que caracteriza por uma associação de fatores de risco cardiovascular, incluindo obesidade central, elevação de glicemia e dislipidemia típica, para tratamento é necessário uma série de medidas farmacológicas ou não para melhorar a qualidade de vida dos seus acometidos. OBJETIVO: Elaborar um guia para identificar as necessidades de saúde de pacientes com Síndrome Metabólica para viabilizar o acompanhamento farmacêutico. METODOLOGIA: O estudo foi realizado na comunidade de Brasília Teimosa, pertencente ao município de Natal, Rio Grande do Norte, com pacientes acometidos por síndrome metabólica, o qual servirão de base para criação de um guia visando identificar as necessidades de saúde destes e fornece uma base de conhecimento e consulta para orientação farmacêutica. RESULTADOS: Com base no questionário elaborado, juntamente com as fichas de acompanhamento, foi elaborado um guia que abrange toda sistemática do acompanhamento farmacêutico atuando diretamente com pacientes com Síndrome metabólica, sendo dividido nas seções: identificação do paciente e da SM, como deve ser feito a abordagem terapêutica, os medicamentos utilizados e quais ações para favorecer melhor qualidade de vida, além de exames essenciais, informações sobre a farmácia popular e do controle de qualidade de medicamentos. CONCLUSÃO: esse estudo buscou identificar prováveis necessidades de saúde em pacientes com síndrome metabólica juntamente com as necessidades dos discentes e profissionais farmacêuticos durante a orientação, com isso foi elaborado um instrumento que auxiliasse nesse processo.TCC Passiflora edulis como terapia adjuvante à insulina na diabetes tipo 1: caracterização de pacientes de um ensaio clínico randomizado(Universidade Federal do Rio Grande do Norte, 2024-12-16) Medeiros, Lorena Barreto de; Rezende, Adriana Augusto; Araújo, Anny Cristine de; https://orcid.org/0000-0002-6562-9876; http://lattes.cnpq.br/1147068814742797; https://orcid.org/0000-0003-2452-4047; http://lattes.cnpq.br/4245215108740331; https://orcid.org/0009-0008-7608-1210; http://lattes.cnpq.br/0121662329654207; Moreira, Francisca Sueli Monte; https://orcid.org/0000-0001-7069-750X; http://lattes.cnpq.br/5764849324594620; Carvalho, Maria Imaculada Conceição Ferreira; http://lattes.cnpq.br/6029941153278427O Diabetes tipo 1, caracterizado pela deficiência de insulina, afeta cerca de 600 mil brasileiros. Em alguns casos, a insulinoterapia é insuficiente e alternativas como a Passiflora edulis (P. edulis) são exploradas como terapias adjuvantes. Este estudo objetiva a caracterização clínico-laboratorial de pacientes diabéticos tipo 1 incluídos em um ensaio clínico randomizado, que utilizou o extrato hidroetanólico de P. edulis como terapia adjuvante a insulina. É um ensaio clínico de fase 2, randomizado, duplo-cego e controlado por placebo realizado no ambulatório de endocrinologia do Hospital de ensino durante 90 dias. Foram incluídos 13 pacientes de um total previsto de 56 pacientes com DM1, e receberam tratamento com extrato de P. edulis (1600mg/dia) adjuvante à insulina (n=28) ou placebo (n=28). Após assinatura do Termo de Consentimento Livre e Esclarecido (TCLE), foi realizada a coleta de sangue e urina de todos os pacientes, aplicação do Hypoglycemia Fear Survey (HFS-II) e monitoramento contínuo da glicemia pelo Freestyle libre. Foram realizadas avaliações dos parâmetros bioquímicos e expressão urinária de nefrina. O cegamento do estudo segue mantido. Foi observado pontuações significativamente mais altas no HFS-II inicial de participantes com mais de 40 anos (p=0,008). Após 90 dias de tratamento com P. edulis, o HFS-II revelou uma diminuição significativa do medo de hipoglicemia (p=0,020). A nefrina foi detectada na urina dos pacientes no início e final do tratamento. Os resultados sugerem a necessidade de um controle glicêmico rigoroso na prevenção de complicações do diabetes e a relevância da nefrina como um biomarcador precoce.Artigo The beneficial effects of rosuvastatin are independent of zinc supplementation in patients with atherosclerosis(Journal of Trace Elements in Medicine and Biology, 2014-04) Evangelista, Karine Cavalcanti Maurício de Sena; Dias, Paula Cristina Silveira; Paiva, Maria Sanali Moura de Oliveira; Ferreira, Diana Quitéria Cabral; Ururahy, Marcela Abbott Galvão; Rezende, Adriana Augusto; Abdalla, Dulcinéia Saes Parra; Pedrosa, Lucia Fatima CamposBackground: Statins have multiple antiatherosclerotic effects, but can reduce blood plasma concentrations of minerals, including zinc. As zinc possesses antiinflammatory and antioxidant effects, low zinc status can promote injuries or inadequate tissue repair in endothelial cells. Metallothionein (MT) expression might modulate responses induced by statins in patients with atherosclerosis. However, research regarding mineral status and the use of statins is scarce. This study evaluated the effects of zinc supplementation on zinc status and expression of the zinc-dependent MT1F and MT2A genes in patients with atherosclerosis treated with rosuvastatin. Methods: A double-blind, randomized clinical trial was performed with 54 participants treated with 10 mg rosuvastatin for 4 months with or without zinc supplementation (30 mg/day). Diet, lipid profile, high-sensitivity reactive protein C (hs-CRP), plasma and erythrocyte zinc concentrations, erythrocyte superoxide dismutase (SOD) activity, and MT1F and MT2A genes expression were analyzed before and after intervention. Results: Rosuvastatin therapy was effective in reducing low- and non-high-density lipoprotein, total cholesterol, triglycerides, and hs-CRP levels, independent of zinc supplementation. Additionally, zinc treatment had no effect on SOD enzyme activity (P = 0.201), plasma (P > 0.671) and erythrocyte (P > 0.123) zinc concentrations, or the pattern of MT1F and MT2A genes expression (P = 0.088 and P = 0.229, respectively). Conclusions: The effectiveness of rosuvastatin treatment is independent of the effects of zinc supplementation. Moreover, rosuvastatin treatment did not have a significant impact on zinc status or MT1F and MT2A genes expression in patients with atherosclerosisArtigo The relationship of the oleic acid level and ECHDC3 mRNA expression with the extent of coronary lesion(Lipids in Health and Disease, 2016) Lima, Severina Carla Vieira Cunha; Duarte, Mychelle Kytchia Rodrigues Nunes; Araújo, Jéssica Nayara Góes de; Duarte, Victor Hugo Rezende; Oliveira, Katiene Macêdo de; Oliveira, Juliana Marinho de; Carioca, Antonio Augusto Ferreira; Bortolin, Raul Hernandes; Rezende, Adriana Augusto; Hirata, Mario Hiroyuki; Hirata, Rosário Domingues; Waitzberg, Dan Linetzky; Luchessi, André Ducati; Silbiger, Vivian Nogueira; https://orcid.org/0000-0001-8268-1986Background: The fatty acid profile is associated with the risk and progression of several diseases, probably via mechanisms including its influence on gene expression. We previously reported a correlation between ECHDC3 upregulation and the severity of acute coronary syndrome. Here, we assessed the relationship of serum fatty acid profile and ECHDC3 expression with the extent of coronary lesion. Methods: Fifty-nine individuals aged 30 to 74 years and undergoing elective cinecoronariography for the first time were enrolled in the present study. The extent of coronary lesion was assessed by the Friesinger index and patients were classified as without lesion (n = 18), low lesion (n = 17), intermediate lesion (n = 17) and major lesion (n = 7). Serum biochemistry, fatty acid concentration, and ECHDC3 mRNA expression in blood were evaluated. Results: Elevated serum levels of oleic acid and total monounsaturated fatty acids were observed in patients with low and intermediate lesion, when compared to patients without lesion (p < 0.05). ECHDC3 mRNA expression was 1. 2 fold higher in patients with low lesion than in patients without lesion (p = 0.020), and 1.8 fold lower in patients with major lesion patients than in patients with low lesion (p = 0.023). Conclusion: Increased levels of monounsaturated fatty acids, especially oleic acid, and ECHDC3 upregulation in patients with coronary artery lesion suggests that these are independent factors associated with the initial progression of cardiovascular disease.